Improving Translational Paradigms in Drug Discovery and Development.

Szczegóły
Abstrakt

Tytuł:: Improving Translational Paradigms in Drug Discovery and Development.
Autorzy:: Williams M; Department of Biological Chemistry and Pharmacology, College of Medicine, Ohio State University, Columbus, Ohio.
Źródło:: Current protocols [Curr Protoc] 2021 Nov; Vol. 1 (11), pp. e273.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Hoboken, NJ : John Wiley & Sons, [2021]-
MeSH Terms:: Biomedical Research*
Drug Discovery*
Animals ; Drug Approval ; Drug Delivery Systems ; Humans ; Research Design
References:: Abedin, Z., Biskup, E., Silet, K., Garbutt, J. M., Kroenke, K., Feldman, M. D., … Pincus, H. A. (2012). Deriving competencies for mentors of clinical and translational scholars. Clinical and Translational Science, 5, 273-280. doi: 10.1111/j.1752-8062.2011.00366.x.
Alberts, B., Kirschner, M. W., Tilghman, S., & Varmus, H. (2014). Rescuing US biomedical research from its systemic flaws. Proceedings of the National Academy of Science USA, 111, 5773-5777. doi: 10.1073/pnas.1404402111.
Alexander, G. C., & Karlawish, J. (2021). The problem of aducanumab for the treatment of Alzheimer disease. Annals of Internal Medicine, 174(9):1303-1304. doi: 10.7326/M21-2603.
Alexandrov, V., Brunner, D., Hanania, T., & Leahy, E. (2015). High-throughput analysis of behavior for drug discovery. European Journal of Pharmacology, 750, 82-89. doi: 10.1016/j.ejphar.2014.11.047.
Angell, M. (2012). Angell on Big Pharma. Econ Talk, November 26, 2012, Library of Economics and Liberty. Available at https://www.econtalk.org/angell-on-big-pharma/.
Arnerić, S. P., Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., … Yule, S. (2017). Cerebrospinal fluid biomarkers for Alzheimer's disease: A view of the regulatory science qualification landscape from the coalition against major diseases CSF biomarker team. Journal of Alzheimer's Disease, 55(1), 19-35. doi: 10.3233/JAD-160573.
Austin, C. P. (2018). Translating translation. Nature Reviews Drug Discovery, 17, 455-456. doi: 10.1038/nrd.2018.27.
Austin, C. P. (2021). Translational misconceptions. Nature Reviews Drug Discovery, 20, 489-490 doi: 10.1038/d41573-021-00008-8.
Avila, A. M., Bebenek, I., Bonzo, J. A., Bourcier, T., Davis Bruno, K. L., Carlson, D. B., … Brown, P. C. (2020). An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs). Regulatory Toxicology and Pharmacology, 114, 104662. doi: 10.1016/j.yrtph.2020.104662.
Baxter, K., Horn, E., Gal-Edd, N., Zonno, K., O'Leary, J., Terry, P. F., & Terry, S. F. (2013). An end to the myth: There is no drug development pipeline. Science Translational Medicine, 5, 171cm1. doi: 10.1126/scitranslmed.3003505.
BIO Biomedtracker Amplion (2016). Clinical Development Success Rates 2006-2015. Available at https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf.
Bush, V. (1945). Section 3 (The importance of basic research), Chapter 3 (Science and the public welfare). In Science: The Endless Frontier-A Report to the President by Vannevar Bush, Director of the Office of Scientific Research and Development, July 1945. Washington, DC: United States Government Printing Office. Available at http://www.nsf.gov/about/history/nsf50/vbush1945_content.jsp.
Butler, D. (2008). Translational research: Crossing the valley of death. Nature, 453, 840-842. doi: 10.1038/453840a.
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013). Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes, 62, 2595-2604. doi: 10.2337/db12-1686.
Cohrs, R. J., Martin, T., Ghahramani, P., Bidaut, L., Higgins, P. J., & Shahzad, A. (2015). Translational Medicine definition by the European Society for Translational Medicine. New Horizons in Translational Medicine, 2, 86-88. doi: 10.1016/j.nhtm.2014.12.002.
Coller, B. S., & Califf, R. M. (2009). Traversing the valley of death: A guide to assessing prospects for translational success. Science Translational Medicine, 1, 10cm9. doi: 10.1126/scitranslmed.3000265.
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014). Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. Nature Reviews Drug Discovery, 13, 419-431. doi: 10.1038/nrd4309.
Coon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., … Stephan, D. A. (2007). A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. Journal of Clinical Psychiatry, 68, 613-618. doi: 10.4088/jcp.v68n0419.
Cummings, J. L. (2020). Translational scoring of candidate treatments for Alzheimer's disease: A systematic approach. Dementia and Geriatric Cognitive Disorders, 49, 22-37. doi: 10.1159/000507569.
Dahlin, J., Inglese, J., & Walters, M. (2015). Mitigating risk in academic preclinical drug discovery. Nature Reviews Drug Discovery, 14, 279-294. doi: 10.1038/nrd4578.
Daudelin, D. H., Peterson, L. E., Welch, L. C., Chandler, R., Pandey, M., Noubary, F., … Selker, H. P. (2019). Implementing common metrics across the NIH Clinical and Translational Science Awards (CTSA) consortium. Journal of Clinical and Translational Science, 4, 16-21. doi: 10.1017/cts.2019.425.
Drucker, D. J. (2016). Never waste a good crisis: Confronting reproducibility in translational research. Cell Metabolism, 24, 348-360. doi: 10.1016/j.cmet.2016.08.006.
Emmert-Buck, M. R. (2014). Translational research: From biological discovery to public benefit (or not). Advanced Biology, 2014, 278789. doi:10.1155/2014/278789.
Enna, S. J., & Williams, M. (2009). Defining the role of pharmacology in the emerging world of translational research. Advances in Pharmacology, 57, 1-30. doi: 10.1016/S1054-3589(08)57001-3.
FDA (2017). 22 Case Studies Where Phase 2 and Phase 3 Trials Had Divergent Results. FDA January, 2017. Available at https://www.fda.gov/about-fda/reports/22-case-studies-where-phase-2-and-phase-3-trials-had-divergent-results.
Felege, C., Hahn, E., Hunter, C., & Gleditsch, R. (2016). Bench, bedside, curbside, and home: Translational research to include transformative change using educational research. Journal of Research Practice, 12, P1. Available at http://jrp.icaap.org/index.php/jrp/article/view/548/453.
FitzGerald, G. A. (2015). Evolution in translational science: Whither the CTSAs? Science Translational Medicine, 7, 284fs15. doi: 10.1126/scitranslmed.aab1596.
Flier, J. S. (2019). Academia and industry: Allocating credit for discovery and development of new therapies. Journal of Clinical Investigation, 129, 2172-2174. doi: 10.1172/JCI129122.
Fontanarosa, P. B., & DeAngelis, C. D. (2002). Basic science and translational research in JAMA. JAMA, 287, 1728. doi: 10.1001/jama.287.13.1728.
Fort, D. G., Herr, T. M., Shaw, P. L., Gutzman, K. E., & Starren, J. B. (2017). Mapping the evolving definitions of translational research. Journal of Clinical and Translational Science, 1, 60-66. doi: 10.1017/cts.2016.10.
Frank, C., Sink, C., Mynatt, L., Rogers, R., & Rappazzo, R. (1996). Surviving the “valley of death”: A comparative analysis. Journal of Technology Transfer, 21, 61-69. doi: 10.1007/BF02220308.
Frearson, J., & Wyatt, P. (2010). Drug discovery in academia-The third way? Expert Opinion on Drug Discovery, 5, 909-919. doi: 10.1517/17460441.2010.506508.
Freedman, S., & Mullane, K. (2017). The academic-industrial complex: Navigating the translational and cultural divide. Drug Discovery Today, 22, 976-993. doi: 10.1016/j.drudis.2017.03.005.
Fudge, N., Sadler, E., Fisher, H. R., Maher, J., Wolfe, C. D., & McKevitt, C. (2016). Optimising translational research opportunities: A systematic review and narrative synthesis of basic and clinician scientists' perspectives of factors which enable or hinder translational research. PloS One, 11, e0160475. doi: 10.1371/journal.pone.0160475.
Fuhrer, R., & Keyes, K. M. (2019). Population mental health in the 21st century: Time to act. American Journal Public Health, 109(S3), S152-S153. doi: 10.2105/AJPH.2019.305200.
Gamo, N. J., Birknow, M. R., Sullivan, D., Kondo, M. A., Horiuchi, Y., Sakurai, T., … Sawa, A. (2017). Valley of death: A proposal to build a "translational bridge" for the next generation. Neuroscience Research, 115, 1-4. doi: 10.1016/j.neures.2016.11.003.
GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study. Lancet, 396, 1204-1222. doi: 10.1016/S0140-6736(20)30925-9 2019.
Gelman, M. (2021). Harvard's Aaron Kesselheim resigns from expert panel in wake of aducanumab OK, blasting FDA for ‘worst drug approval decision in recent U.S. history'. EndPoints News, June 10, 2021. Available at https://endpts.com/harvards-aaron-kesselheim-resigns-from-expert-panel-in-wake-of-aducanumab-ok-blasting-fda-for-worst-drug-approval-decision-in-recent-u-s-history/.
Ghoda, L. Y., Rosen, S. T., & Kwak, L. W. (2020). The changing investment in translational science by academic medical centers: HOPE in the Valley of Death. Journal of Clinical Investigation, 130, 3333-3335. doi: 10.1172/JCI138640.
Gilliland, C. T., Zuk, D., Kocis, P., Johnson, M., Hay, S., Hajduch, M., … Ussi, A. E. (2016). Putting translational science on to a global stage. Nature Reviews Drug Discovery, 15, 217-218. doi: 10.1038/nrd.2016.33.
Gohar, F., Gohar, A., Hülskamp, G., & Debus, O. (2018). The translational medicine professional: A bridge between bench and bedside? Frontiers in Medicine, 5, 294. doi: 10.3389/fmed.2018.00294.
Han, X., Williams, S. R., & Zuckerman, B. L. (2018). A snapshot of translational research funded by the National Institutes of Health (NIH): A case study using behavioral and social science research awards and Clinical and Translational Science Awards funded publications. PLoS ONE, 13, e0196545. doi: 10.1371/journal.pone.0196545.
Hartung, T. (2013). Look back in anger-what clinical studies tell us about preclinical work. ALTEX, 30, 275-291. doi: 10.14573/altex.2013.3.275.
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014). Clinical development success rates for investigational drugs. Nature Biotechnology, 32, 40−51. doi: 10.1038/nbt.2786.
Hay, S. I., Rao, P. C., Dolecek, C., Day, N., Stergachis, A., Lopez, A. D., & Murray, C. (2018). Measuring and mapping the global burden of antimicrobial resistance. BMC Medicine, 16, 78. doi: 10.1186/s12916-018-1073-z.
Hegyi, P., Petersen, O. H., Holgate, S., Erőss, B., Garami, A., Szakács, Z., … Szentesi, A. (2020). Academia Europaea position paper on translational medicine: The cycle model for translating scientific results into community benefits. Journal of Clinical Medicine, 9, 1532. doi: 10.3390/jcm9051532.
Hingorani, A. D., Kuan, V., Finan, C., Kruger, F. A., Gaulton, A., Chopade, S., … Casas, J. P. (2019). Improving the odds of drug development success through human genomics: Modelling study. Science Report, 9, 18911. doi: 10.1038/s41598-019-54849-w.
Hobson, K. (2011). Former Merck Head Vagelos Says NIH Should Stick to Basic Research. Wall Street Journal, April 15, 2011. Available at https://www.wsj.com/articles/BL-HEB-47984.
Horrobin, D. F. (2003). Modern biomedical research: An internally self-consistent universe with little contact with reality? Nature Reviews Drug Discovery, 2, 151-154. doi: 10.1038/nrd1012.
Horowitz, C. R., Shameer, K., Gabrilove, J., Atreja, A., Shepard, P., Goytia, C. N., … Galvez, M. P. (2017). Accelerators: Sparking innovation and transdisciplinary team science in disparities research. International Journal of Environmental Research and Public Health, 14, 225. doi: 10.3390/ijerph14030225.
Hudson, J., & Khazragui, H. F. (2013). Into the valley of death: Research to innovation. Drug Discovery Today, 18, 610-613. doi: 10.1016/j.drudis.2013.01.012.
Ioannidis, J., Cripps, S., & Tanner, M. A. (2020). Forecasting for COVID-19 has failed. International Journal of Forecasting, Online ahead of print. doi: 10.1016/j.ijforecast.2020.08.004.
Janiaud, P., Irony, T., Russek-Cohen, E., & Goodman, S. N. (2021). U.S. Food and Drug Administration reasoning in approval decisions when efficacy evidence is borderline, 2013-2018. Annals of Internal Medicine, 10.7326/M21-2918. Advance online publication. https://doi.org/10.7326/M21-2918.
Kaiser, J. (2019). NIH center struggles to speed new therapies. Science, 365, 1363. doi: 10.1126/science.365.6460.1363.
Kaltenboeck, A., Mehlman, A., & Pearson, S. D. (2021). Potential policy reforms to strengthen the accelerated approval pathway. Journal of Comparative Effectiveness Research, Online ahead of print. doi: 10.2217/cer-2021-0184.
Kesselheim, A. S., & Avorn, J. (2016). Approving a problematic muscular dystrophy drug: Implications for FDA policy. Journal of the American Medical Association, 316(22), 2357−2358. doi: 10.1001/jama.2016.16437.
Kimmelman, J., Mogil, J. S., & Dirnagl, U. (2014). Distinguishing between exploratory and confirmatory preclinical research will improve translation. PLoS Biology, 12, e1001863. doi: 10.1371/journal.pbio.1001863.
King, E. A., Davis, J. W., & Degner, J. F. (2019). Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genetics, 15, e1008489. doi: 10.1371/journal.pgen.1008489.
Khoury, M. J., Gwinn, M., Yoon, P. W., Dowling, N., Moore, C. A., & Bradley, L. (2007). The continuum of translation research in genomic medicine: How can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genetics Medicine, 9, 665-674. doi: 10.1097/GIM.0b013e31815699d0.
Knopman, D. S., Jones, D. T., & Greicius, M. D. (2021). Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers & Dementia, 17, 696-701. doi: 10.1002/alz.12213.
Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Review of Drug Discovery, 3, 711-716. doi: 10.1038/nrd1470.
LaMattina, J. (2012). The NIH is going to discover drugs-really? Forbes, May 15, 2012. Available at https://www.forbes.com/sites/johnlamattina/2012/05/15/the-nih-is-going-to-discover-drugs-really/?sh=1f8dc1135a57.
Lazebnik, Y. (2015). Are scientists a workforce?-Or, how Dr. Frankenstein made biomedical research sick: A proposed plan to rescue US biomedical research from its current 'malaise' will not be effective as it misdiagnoses the root cause of the disease. EMBO Report, 16, 1592-1600. doi: 10.15252/embr.201541266.
Licino, J. (2011). Translational Psychiatry: Leading the transition from the cesspool of devastation to a place where the grass is really greener. Translational Psychiatry, 1, e1. doi: 10.1038/tp.2011.3.
Lowe, D. (2011). Maybe it really is that hard? In the Pipeline, May 24, 2011, Available at https://blogs.sciencemag.org/pipeline/archives/2011/05/24/maybe_it_really_is_that_hard.
Lowe, D. (2012). Eroom's law. In the Pipeline. March 8, 2012. Available at https://www.science.org/content/blog-post/eroom-s-law.
Lowe, D. (2019). The latest on drug failure and approval rates. In the Pipeline, May 9, 2019. Available at https://blogs.sciencemag.org/pipeline/archives/2019/05/09/the-latest-on-drug-failure-and-approval-rates.
Lowe, D. (2020). Opening the lid on Sarepta's drug approvals. In the Pipeline, January 2, 2020. Available at https://blogs.sciencemag.org/pipeline/archives/2020/01/22/opening-the-lid-on-sareptas-drug-approvals.
Luft, F. C. (1997). The role of the general clinical research center in promoting patient-oriented research into the mechanisms of disease. Journal of Molecular Medicine (Berlin), 75(8), 545-550.
Mahase, E. (2021). FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway. BMJ, 374, n1898. doi: 10.1136/bmj.n1898.
McAteer, M. A., O'Connor, J., Koh, D. M., Leung, H. Y., Doran, S. J., Jauregui-Osoro, M., … Punwani, S. (2021). Introduction to the National Cancer Imaging Translational Accelerator (NCITA): A UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers. British Journal of Cancer, 1-4. Online ahead of print. doi: 10.1038/s41416-021-01497-5.
McGonigle, P., & Williams, M. (2017). Preclinical pharmacology and toxicology-Contributions to the translational interface. Reference Module in Biomedical Sciences. doi: 10.1016/B978-0-12-801238-3.05232-9.
McMaughan, D. J., Oloruntoba, O., & Smith, M. L. (2020). Socioeconomic status and access to healthcare: Interrelated drivers for healthy aging. Frontiers in Public Health, 8, 231. doi: 10.3389/fpubh.2020.00231.
Mogil, J., & Macleod, M. (2017). No publication without confirmation. Nature, 542, 409-411 doi: 10.1038/542409a.
Mullane, K., & Williams, M. (2012). Translational semantics and infrastructure: Another search for the Emperor's clothes. Drug Discovery Today, 17, 459-468. doi: 10.1016/j.drudis.2012.01.004.
Mullane, K., & Williams, M. (2019). Preclinical models of Alzheimer's disease: Relevance and translational validity. Current Protocol Pharmacology, 84, e57. doi: 10.1002/cpph.57.
Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery, 8, 959-968. doi: 10.1038/nrd2961.
NASEM (2020). National Academies of Sciences, Engineering, and Medicine. 2020. The role of NIH in drug development innovation and its impact on patient access: Proceedings of a workshop. Washington, DC: The National Academies Press. doi: 10.17226/25591.
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery, 10, 428-438. doi: 10.1038/nrd3405.
Parrish, M. C., Tan, Y. J., Grimes, K. V., & Mochly-Rosen, D. (2019). Surviving in the valley of death: Opportunities and challenges in translating academic drug discoveries. Annual Review of Pharmacology and Toxicology, 59, 405-421. doi: 10.1146/annurev-pharmtox-010818-021625.
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery, 9, 203-214. doi: 10.1038/nrd3078.
Perlmutter, J. S. (2021). Moving the U.S. Food and Drug Administration forward. Annals of Internal Medicine, 10.7326/M21-3393. Advance online publication. https://doi.org/10.7326/M21-3393.
Perrone, R. D., Mouksassi, M. S., Romero, K., Czerwiec, F. S., Chapman, A. B., Gitomer, B. Y., … Marier, J. F. (2017). A drug development tool for trial enrichment in patients with autosomal dominant polycystic kidney disease. Kidney International Reports, 2, 451-460. doi: 10.1016/j.ekir.2017.02.011.
Pound, P., & Ritskes-Hoitinga, M. (2018). Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. Journal of Translational Medicine, 16, 304. doi: 10.1186/s12967-018-1678-1.
Refoundable (2020). Life after Eroom's law. Refoundable.com, March 27, 2020. Available at https://refoundable.com/research/life-after-erooms-law-interview-with-jack-scannell#s1.
Raymer, R., Milovanovic, J., Grover, A., Gallo, Gwizdak, S., Ferraro, J., & Cardinal, M. (2021). Aducanumab's groundbreaking approval brings mixed perspectives. Halloran Insights, July 20, 2021. Available at https://www.hallorancg.com/2021/07/20/aducanumabs-groundbreaking-approval-brings-mixed-perspectives/.
Rosenberg, R. N. (2003). Translating biomedical research to the bedside: A national crisis and a call to action. JAMA, 289, 1305-1306. doi: 10.1001/jama.289.10.1305.
Ringel, M. S., Scannell, J. W., Baedeker, M., & Schulze, U. (2020). Breaking Eroom's Law. Nature Reviews Drug Discovery, 19, 833-834. doi: 10.1038/d41573-020-00059-3.
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004). Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews Drug Discovery, 3, 353-359. doi: 10.1038/nrd1346.
Rubin, R. (2021). Recently approved Alzheimer drug raises questions that might never be answered. JAMA, 326, 469-472. doi: 10.1001/jama.2021.11558.
Rubio, D. M., Schoenbaum, E. E., Lee, L. S., Schteingart, D. E., Marantz, P. R., Anderson, K. E., … Esposito, K. (2010). Defining translational research: Implications for training. Academic Medicine, 85(3), 470-475. doi: 10.1097/ACM.0b013e3181ccd618.
Saladino, V., Algeri, D., & Auriemma, V. (2020). The psychological and social impact of Covid-19: New perspectives of well-being. Frontiers in Psychology, 11, 577684. doi: 10.3389/fpsyg.2020.577684.
Scannell, J. W., & Bosley, J. (2016). When quality beats quantity: Decision theory, drug discovery, and the reproducibility crisis. PLoS ONE, 11, e0147215. doi: 10.1371/journal.pone.0147215.
Scannell, J., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 11, 191-200. doi: 10.1038/nrd3681.
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016). Changing R&D models in research-based pharmaceutical companies. Journal of Translational Medicine, 14, 105. doi 10.1186/s12967-016-0838-4.
Seyhan, A. A. (2019). Lost in translation: The valley of death across preclinical and clinical divide-identification of problems and overcoming obstacles. Translational Medicine Communications, 4, 18. doi: 10.1186/s41231-019-0050-7.
Slusher, B. S., Conn, P. J., Frye, S., Glicksman, M., & Arkin, M. (2013). Bringing together the academic drug discovery community. Nature Reviews Drug Discovery, 12, 811-812. doi: 10.1038/nrd4155.
Sneader, W. (1985). Drug discovery: The evolution of modern medicines. Chichester, UK: Wiley.
Sung, N. S., Crowley, W. F. Jr, Genel, M., Salber, P., Sandy, L., Sherwood, L. M., … Rimoin, D. (2003). Central challenges facing the national clinical research enterprise. JAMA, 289, 1278-1287. doi: 10.1001/jama.289.10.1278.
Swinney, D. C., & Anthony, J. (2011). How were new medicines discovered? Nature Reviews Drug Discovery, 10, 507-519. doi: 10.1038/nrd3480.
Szilagyi, P. G. (2009). Translational research and pediatrics. Academic Pediatrics, 9, 71-80. doi: 10.1016/j.acap.2008.11.002.
Takebe, T., Imai, R., & Ono, S. (2018). The current status of drug discovery and development as originated in United States Academia: The influence of industrial and academic collaboration on drug discovery and development. Clinical and Translational Science, 11, 597-606. doi: 10.1111/cts.12577.
Tashkin, D. P., Amin, A. N., & Kerwin, E. M. (2020). Comparing randomized controlled trials and real-world studies in chronic obstructive pulmonary disease pharmacotherapy. International Journal of Chronic Obstructive Pulmonary Disease, 15, 1225-1243. doi: 10.2147/COPD.S244942.
Terzic, A., & Waldman, S. (2011). Chronic diseases: The emerging pandemic. Clinical and Translational Science, 4, 225-226. doi: 10.1111/j.1752-8062.2011.00295.x.
Triunfol, M., & Gouveia, F. C. (2021). What's not in the news headlines or titles of Alzheimer disease articles? #InMice. PLoS Biology, 19, e3001260. doi: 10.1371/journal.pbio.3001260.
Tsai, J., O'Toole, T., & Kearney, L. K. (2017). Homelessness as a public mental health and social problem: New knowledge and solutions. Psychological Services, 14, 113-117. http://doi.org/10.1037/ser0000164.
Uher, J. (2018). Quantitative data from rating scales: An epistemological and methodological enquiry. Frontiers in Psychology, 9, 2599. doi: 10.3389/fpsyg.2018.02599.
Wagner, J. A., Dahlem, A. M., Hudson, L. D., Terry, S. F., Altman, R. B., Gilliland, C. T., … Austin, C. P. (2018a). Application of a dynamic map for learning, communicating, navigating, and improving therapeutic development. Clinical and Translational Science, 11, 166-174. doi: 10.1111/cts.12531.
Wagner, J., Dahlem, A. M., Hudson, L. D., Terry, S. F., Altman, R. B., Gilliland, C. T., … Austin, C. P. (2018b). A dynamic map for learning, communicating, navigating and improving therapeutic development. Nature Reviews Drug Discovery, 17, 150. doi: 10.1038/nrd.2017.217.
Wang, S. S. (2011). Sanofi's Zerhouni On Translational Research: No Simple Solution. Wall St. J., May 20, 2011. Available at https://www.wsj.com/articles/BL-HEB-48098.
Westfall, J. M., Mold, J., & Fagnan, L. (2007). Practice-based research-"Blue Highways" on the NIH roadmap. JAMA, 297, 403-406. doi: 10.1001/jama.297.4.403.
Westfall, J. M., & Mensah, G. A. (2018). T4 translational moonshot: Making cardiovascular discoveries work for everyone. Circulation Research, 122, 210-212. doi: 10.1161/CIRCRESAHA.117.312273.
Wehling, M. (2009). Assessing the translatability of drug projects: What needs to be scored to predict success? Nature Reviews Drug Discovery., 8, 541-546. doi: 10.1038/nrd2898.
Weisbach, J. A., & Moos, W. H. (1995). Diagnosing the decline of major pharmaceutical research laboratories: A prescription for drug companies. Drug Development Research, 34, 243-259. doi: 10.1002/ddr.430340302.
Wendler, A., & Wehling, M. (2012). Translatability scoring in drug development: Eight case studies. Journal of Translational Medicine, 10, 39. doi: 10.1186/1479-5876-10-39.
Wendler, A., & Wehling, M. (2018). Translatability score revisited: Differentiation for distinct disease areas. Journal of Translational Medicine, 15, 226. doi: 10.1186/s12967-017-1329-y.
Whiteside, G. T., Pomonis, J. D., & Kennedy, J. D. (2013). An industry perspective on the role and utility of animal models of pain in drug discovery. Neuroscience Letters, 557(Pt A), 65-72. doi: 10.1016/j.neulet.2013.08.033.
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA, 324, 782-793. doi: 10.1001/jama.2020.12839.
Williams, M. (2007). Enabling technologies in drug discovery: the technical and cultural integration of the new with the old. Comprehensive Medicinal Chemistry II, 2, 265-297. doi: 10.1016/B0-08-045044-X/00056-0.
Williams, S. (2016). Building a translational medicine powerhouse in China. Science, June 24, 2016. Available at https://www.sciencemag.org/features/2016/06/building-translational-medicine-powerhouse-china.
Woodcock, J., & Woosley, R. (2008). The FDA critical path initiative and its influence on new drug development. Annual Review of Medicine, 59, 1-12. doi: 10.1146/annurev.med.59.090506.155819.
Woolf, S. H. (2008). The meaning of translational research and why it matters. JAMA, 299, 211-213. doi: 10.1001/jama.2007.26.
Wright, A., Salazar, A., Mirica, M., Volk, L. A., & Schiff, G. D. (2020). The invisible epidemic: neglected chronic disease management during COVID-19. Journal of General Internal Medicine, 35, 2816-2817. doi: 10.1007/s11606-020-06025-4.
Yezierski, R. P., & Hansson, P. (2018). Inflammatory and neuropathic pain from bench to bedside: what went wrong? Journal of Pain, 19, 571-588. doi: 10.1016/j.jpain.2017.12.261.
Zerhouni, E. (2003). Medicine. The NIH Roadmap. Science, 302, 63-72. doi: 10.1126/science.1091867.
Zhang, A. D., Puthumana, J., Downing, N. S., Shah, N. D., Krumholz, H. M., & Ross, J. S. (2020). Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995-2017. JAMA Network Open, 3, e203284. doi: 10.1001/jamanetworkopen.2020.3284.
Zywicki, T. J., & Koopman, C. (2017) The Changing of the Guard: The political economy of administrative bloat in American Higher Education. George Mason Law Economic Research Paper No. 17-12, Available at https://ssrn.com/abstract=2939915 or http://doi.org/10.2139/ssrn.2939915.
Contributed Indexing:: Keywords: attrition rates; drug discovery; translation; translational scoring; valleys of death
Entry Date(s):: Date Created: 20211115 Date Completed: 20211117 Latest Revision: 20211117
Update Code:: 20240104
DOI:: 10.1002/cpz1.273
PMID:: 34780124
: Czasopismo naukowe

Despite improved knowledge regarding disease causality, new drug targets, and enabling technologies, the attrition rate for compounds entering clinical trials has remained consistently high for several decades, with an average 90% failure rate. These failures are manifested in an inability to reproduce efficacy findings from animal models in humans and/or the occurrence of unexpected safety issues, and reflect failures in T1 translation. Similarly, an inability to sequentially demonstrate compound efficacy and safety in Phase IIa, IIb, and III clinical trials represents failures in T2 translation. Accordingly, T1 and T2 translation are colloquially termed 'valleys of death'. Since T2 translation dealt almost exclusively with clinical trials, T3 and T4 translational steps were added, with the former focused on facilitating interactions between laboratory- and population-based research and the latter on 'real world' health outcomes. Factors that potentially lead to T1/T2 compound attrition include: the absence of biomarkers to allow compound effects to be consistently tracked through development; a lack of integration/'de-siloing' of the diverse discipline-based and technical skill sets involved in drug discovery; the industrialization of drug discovery, which via volume-based goals often results in quantity being prioritized over quality; inadequate project governance and strategic oversight; and flawed decision making based on unreliable/irreproducible or incomplete data. A variety of initiatives have addressed this problem, including the NIH National Center for Advancing Translational Sciences (NCATS), which has focused on bringing an unbiased academic perspective to translation, to potentially revitalize the process. This commentary provides an overview of the basic concepts involved in translation, along with suggested changes in the conduct of biomedical research to avoid valleys of death, including the use of Translational Scoring as a tool to avoid translational attrition and the impact of the FDA Accelerated Approval Pathway in lowering the hurdle for drug approval. © 2021 Wiley Periodicals LLC.
(© 2021 Wiley Periodicals LLC.)

Informacja